Clinical trials: Influenza Vaccines
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes
The objective of this study is to evaluate the immunogenicity and safety of one or two doses of GSK Biologicals' investigational influenza vaccine GSK2340272A, manufactured using two different processes, in adults aged 18 to 60…
- Trial name
- NCT00992511
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 4 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
The purpose of this study was to demonstrate the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza. The study was a placebo controlled, double blinded trial at a single site.
- Trial name
- NCT01688297
- Testing
- VXA-A1.1 Oral Vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata)…
- Trial name
- NCT01712984
- Testing
- Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
- Where
- 38 sites in United States
- Volunteers
- 3,360 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Prevention of Influenza
Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine
A randomized, blind, positive vaccine control trial was designed.A total of 2550 subjects aged 6-35 months were randomly assigned to the low dose (0.25ml/ dose) group, the high dose (0.5ml/ dose) group and the control group in a…
- Trial name
- NCT05642078
- Testing
- Investigational Vaccine(0.25ml/vial), Investigational Vaccine(0.5ml/vial), Active compared Vaccine
- Where
- China
- Volunteers
- 2,550 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pandemic Influenza
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.
- Trial name
- NCT00519389
- Testing
- H5N1 VLP Vaccine
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza Infection
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
The objectives of this phase 2 study are to evaluate immunogenicity, safety and tolerability of AD07030, a trivalent influenza virus antigens vaccine, given intranasally in 2 doses in healthy adult volunteers.
- Trial name
- NCT03784885
- Testing
- AD07010, Inactivated trivalent influenza vaccine
- Where
- Taiwan
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
Influenza
Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO (World Health Organization) and CHMP (Committee for Medicinal Products for Human Use)…
- Trial name
- NCT00354016
- Testing
- preservative free inactivated split influenza vaccine using the strain composition 2006/2007
- Where
- 2 sites in Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2016-2017 influenza season
- Trial name
- FluMist (NCT02743117)
- Testing
- Monovalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Orthomyxoviridae Infections
Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
Primary Objective: To provide the Center for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2008-2009 formulation of the inactivated, split-virion influenza vaccine Fluzone® for…
- Trial name
- NCT00755274
- Testing
- Influenza Virus Vaccine No Preservative: Pediatric Dose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Flu
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to < 9 years of age, and in adults 18 to < 65 years of age, and to describe the…
- Trial name
- NCT03308825
- Testing
- Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
The purpose of this study is to assess in healthy subjects the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses of CR6261, a monoclonal antibody against influenza A viruses.
- Trial name
- NCT01406418
- Testing
- CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Study of Quadrivalent Influenza Vaccine Among Children
The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1), and the investigational TIV containing the…
- Trial name
- NCT01240746
- Testing
- Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative
- Where
- 67 sites in United States
- Volunteers
- 4,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in…
- Trial name
- NCT05446740
- Testing
- GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3
- Where
- 7 sites in Belgium, Canada and 1 more
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Influenza
Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.
This study is aimed to confirm the lot-to-lot consistency of 3 consecutive batches of 'GC FLU® Pre-filled Syringe Injection' and 'GC FLU® Injection' in the lot-to-lot
- Trial name
- NCT02067117
- Testing
- GC FLU® Injection, GC FLU® Pre-filled Syringe Injection
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza Infection
Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants
The purpose of this study is to evaluate the immunogenicity and safety of TAK-850 administered subcutaneously as a single dose versus influenza HA vaccination in an exploratory manner.
- Trial name
- NCT02555618
- Testing
- TAK-850, Influenza HA vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Adult Volunteers
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008
The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008.
- Trial name
- NCT01333462
- Testing
- NB-1008, Control
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Influenza
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist…
- Trial name
- NCT00192491
- Testing
- FluMist
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Cold, Cold Symptom
Ability of Beta-glucan Supplementation to Augment Immune Function
This proposed study is designed to assess the efficacy of a capsule containing beta-glucan taken orally daily as compared to a placebo capsule on the URTI symptoms, and the immune response change in marathon runners
- Conditions
- Cold, Cold Symptom, Flu, Flu Symptom
- Trial name
- NCT03769012
- Testing
- Beta-Glucan
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Influenza
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice…
- Trial name
- NCT00453999
- Testing
- Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
- Where
- 83 sites in United States, Australia and 5 more
- Volunteers
- 137 people
- Sponsor
- BioCryst Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.